Treatment Strategies for Non-Small Cell Lung Cancer with Common Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Feb 11

PMID 36765587

Authors

Julian A Marin-Acevedo

Bruna Pellini

ErinMarie O Kimbrough

J Kevin Hicks

Alberto Chiappori

Affiliations

Soon will be listed here.

Abstract

The development of targeted therapies over the past two decades has led to a dramatic change in the management of -mutant non-small cell lung cancer (NSCLC). While there are currently five approved EGFR tyrosine kinase inhibitors (TKIs) for treating -mutant NSCLC in the first-line setting, therapy selection after progression on EGFR TKIs remains complex. Multiple groups are investigating novel therapies and drug combinations to determine the optimal therapy and treatment sequence for these patients. In this review, we summarize the landmark trials and history of the approval of EGFR TKIs, their efficacy and tolerability, and the role of these therapies in patients with central nervous system metastasis. We also briefly discuss the mechanisms of resistance to EGFR TKIs, ongoing attempts to overcome resistance and improve outcomes, and finalize by offering treatment sequencing recommendations.

Citing Articles

Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasis.

Hsu C, Chiu L, Ko H, Wu C, Kuo S, Ju J Oncol Lett. 2025; 29(4):201.

PMID: 40070793 PMC: 11894514. DOI: 10.3892/ol.2025.14947.

Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients - a nationwide and longitudinal study.

Nyen J, Booth A, Husby O, Bugge C, Engebretsen I, Oteiza F Front Oncol. 2025; 15:1506041.

PMID: 40052133 PMC: 11882418. DOI: 10.3389/fonc.2025.1506041.

Comprehensive analysis of genomic alterations and novel prognostic biomarkers, and establishment of prediction models of metastasis in metastatic non-small cell lung cancer.

Wang K, Ye M, Mo Z, Huang X, Li Y, Wei S J Cancer. 2025; 16(1):339-350.

PMID: 39744567 PMC: 11660132. DOI: 10.7150/jca.97070.

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs.

Ma J, Huang L, Han C Ther Adv Med Oncol. 2024; 16:17588359241289648.

PMID: 39434954 PMC: 11492187. DOI: 10.1177/17588359241289648.

ctDNA Hypermethylation is a Prognostic Indicator in EGFR-TKI-Treated Advanced Non-Small Cell Lung Cancer.

Liu B, Zhao B, Yin Y, Jiang Y, Feng X, Wang L Cancer Manag Res. 2024; 16:1405-1416.

PMID: 39411686 PMC: 11476527. DOI: 10.2147/CMAR.S474241.

References

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

Fukuoka M, Wu Y, Thongprasert S, Sunpaweravong P, Leong S, Sriuranpong V . Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29(21):2866-74. DOI: 10.1200/JCO.2010.33.4235. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Romaniello D, Marrocco I, Nataraj N, Ferrer I, Drago-Garcia D, Vaknin I . Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers (Basel). 2020; 12(9). PMC: 7563838. DOI: 10.3390/cancers12092394. View

Hsu P, Huang C, Wang C, Kuo S, Chu C, Tung P . The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. Pharmaceuticals (Basel). 2020; 13(11). PMC: 7690705. DOI: 10.3390/ph13110331. View

Tulchinsky E, Demidov O, Kriajevska M, Barlev N, Imyanitov E . EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. Biochim Biophys Acta Rev Cancer. 2018; 1871(1):29-39. DOI: 10.1016/j.bbcan.2018.10.003. View

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

10.

Mok T, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S . Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018; 36(22):2244-2250. DOI: 10.1200/JCO.2018.78.7994. View

11.

Song C, Yang X . Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review. Front Oncol. 2022; 12:834585. PMC: 9047874. DOI: 10.3389/fonc.2022.834585. View

12.

Passiglia F, Raez L, Rolfo C . Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?. J Thorac Dis. 2018; 10(Suppl 9):S1076-S1080. PMC: 5949407. DOI: 10.21037/jtd.2018.03.92. View

13.

Cohen M, Johnson J, Chen Y, Sridhara R, Pazdur R . FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005; 10(7):461-6. DOI: 10.1634/theoncologist.10-7-461. View

14.

Yang J, Schuler M, Popat S, Miura S, Heeke S, Park K . Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020; 15(5):803-815. DOI: 10.1016/j.jtho.2019.12.126. View

15.

Janne P, Baik C, Su W, Johnson M, Hayashi H, Nishio M . Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, -Mutated Non-Small Cell Lung Cancer. Cancer Discov. 2021; 12(1):74-89. PMC: 9401524. DOI: 10.1158/2159-8290.CD-21-0715. View

16.

Yap T, Macklin-Doherty A, Popat S . Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. Eur J Cancer. 2016; 70:12-21. DOI: 10.1016/j.ejca.2016.10.014. View

17.

Offin M, Chan J, Tenet M, Rizvi H, Shen R, Riely G . Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. J Thorac Oncol. 2019; 14(10):1784-1793. PMC: 6764905. DOI: 10.1016/j.jtho.2019.06.002. View

18.

Nogami N, Barlesi F, Socinski M, Reck M, Thomas C, Cappuzzo F . IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. J Thorac Oncol. 2021; 17(2):309-323. DOI: 10.1016/j.jtho.2021.09.014. View

19.

Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A . LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013; 31(27):3335-41. DOI: 10.1200/JCO.2012.45.0981. View

20.

Paz-Ares L, Ciuleanu T, Cobo M, Schenker M, Zurawski B, Menezes J . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):198-211. DOI: 10.1016/S1470-2045(20)30641-0. View